HOXA9 and CD163 potentiate pancreatic ductal adenocarcinoma progression
Abstract Background The role of HOXA9 requires investigations in pancreatic ductal adenocarcinoma (PDAC) as HOXA9 inhibitors are being developed. HOXA9 might attract CD163 expressed tumor associated macrophages (TAM) and could affect PDAC prognosis. This work aims to study the expression and relevan...
Saved in:
| Main Authors: | Aiat Shaban Hemida, Mohamed Mohamady Ahmed, Mona Saeed Tantawy |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-10-01
|
| Series: | Diagnostic Pathology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13000-024-01563-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Relationship of Immunohistochemical Expression of CD86/CD163 Positive Intratumoral Macrophages with Prognosis of Pancreatic Ductal Adenocarcinoma
by: Goran Glavčić, et al.
Published: (2024-01-01) -
The Role of Soluble CD163 (sCD163) in Human Physiology and Pathophysiology
by: Andriana Plevriti, et al.
Published: (2024-10-01) -
Identification of HOXA9 methylation as an epigenetic biomarker predicting prognosis and guiding treatment choice in acute myeloid leukemia
by: Fei Xie, et al.
Published: (2025-02-01) -
Contribution of gut microbiome to pancreatic ductal adenocarcinoma development
by: D. V. Zaitsev, et al.
Published: (2025-05-01) -
Pancreatic ductal adenocarcinoma arising from the pancreatic parenchyma compressed by a huge pancreatic lipoma: a case report
by: Seiji Nakahara, et al.
Published: (2023-08-01)